Long term risk of infections in Hodgkin lymphoma long‐term survivors

Background Long-term side effects associated with the treatment of Hodgkin’s lymphoma (HL) have frequently been reported during the last decades. Studies have shown increased mortality in HL survivors. Following Hodgkin’s lymphoma, second malignancies (SM) and cardiovascular disease (CVD) are the most common causes of death in individuals treated for HL. This study investigates the incidence of side effects such as SM, CVD and infections in a cohort diagnosed with HL in Sweden between 1965 and 1995. In addition, this study identifies covariate risk factors for late side effects in order to develop strategies that prevent morbidity and mortality in HL survivors. Methods Using the Swedish Cancer Registry (SCR) at the National Board of Health and Welfare and the Multi-Generation Registry at Statistics (MGR) Sweden, we identified 6946 individuals diagnosed with HL between the years 1965 and 1995, and their first degree relatives (FDR) (n=17 858). In addition we identified the malignancies and inpatient care for CVD and infections for the HL cohort and their FDR. The standard incidence ratio (SIR) was calculated for the risk of SM, CVD and infections. For SM and CVD the risk also was stratified and calculated for family history of disease. The Swedish Hodgkin Intervention and Prevention study (SHIP), a prospective study, invited 702 individuals treated for HL at the age of 45 years or younger and who were treated in the region of Skane, Uppsala or Umea. The participants completed a questionnaire and were invited to an out-patient visit to an oncologist with clinical examination and blood tests. Any pathological findings were referred for further investigation. Results An increased risk for SM in HL long-term survivors was observed and seems to increase with the number of FDRs with cancer. There was also an increased risk for inpatient care due to congestive heart failure (CHF) and coronary artery disease (CAD). A family history of CHF and CAD further increased the risk for these diseases. The risk for inpatient care due to infections was increased and remained increased after 20 years or longer. The risk for infections was associated with splenectomy and hypothyroidism. Radiotherapy was an independent risk factor for cardiovascular disease in the cohort of the prospective study. ConclusionLong-term survivors from HL have an increased risk for developing late side effects such as SM, CVD and infections. Since many HL patients are young and the cure rate from the disease is high, it is of great importance to offer focused surveillance programs to selected individuals who are at high risk, e.g. individuals who received radiotherapy as part of their treatment and who have other known risk factors for cardiovascular disease such as hypertension, hypercholesterolemia, family history and smoking.

[1]  B. Malmer,et al.  Long‐term risk of cardiovascular disease in Hodgkin lymphoma survivors—Retrospective cohort analyses and a concept for prospective intervention , 2009, International journal of cancer.

[2]  A. Hart,et al.  Late cardiotoxicity after treatment for Hodgkin lymphoma. , 2007, Blood.

[3]  M. Björkholm,et al.  A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma , 2004, Journal of internal medicine.

[4]  D. Waghorn,et al.  Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed , 2001, Journal of clinical pathology.

[5]  T. Lister,et al.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Mauch,et al.  Controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin's disease. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Björkholm,et al.  Immune deficiency in family members of patients with Hodgkin's disease , 1990, Cancer.

[8]  A. Dawson,et al.  Splenectomy and infection in Hodgkin's disease , 1983, The British journal of surgery.

[9]  W. Krivit Overwhelming postsplenectomy infection , 1977, American journal of hematology.

[10]  H. Holte,et al.  Infection after splenectomy for Hodgkin's disease. , 1990, Acta oncologica.